Early Outcomes With HeartWare HVAD as Bridge to Transplant in Children: A Single Institution Experience

Giuseppe Ferro*, Raghav Murthy, Derek Williams, Vinod A. Sebastian, Joseph M. Forbess, Kristine J. Guleserian

*Corresponding author for this work

Research output: Contribution to journalArticle

14 Scopus citations


The HeartWare HVAD has been used as a bridge to cardiac transplantation in the pediatric population. We describe outcomes following HeartWare HVAD implantation at a single center. A retrospective chart review was performed of all HeartWare HVAD implants performed at our institution between May 2013 and March 2015. Eight children between the ages of 9 and 17 years underwent HVAD implantation as a bridge to transplant (N=7 cardiomyopathy, N=1 complex single ventricle). There was one operative death in the complex single ventricle patient. Seven patients (87%) were successfully bridged to transplant. Median time of support was 24.5 days (range, 6-91 days). All transplanted patients are alive and well at a median follow-up of 448 days. Our results demonstrated that mechanical support with HeartWare HVAD is feasible in patients of varying sizes (from older children to adolescents).

Original languageEnglish (US)
Pages (from-to)85-89
Number of pages5
JournalArtificial organs
Issue number1
StatePublished - Jan 1 2016



  • Cardiac transplantation
  • Heart failure
  • Pediatric
  • Ventricular assist device

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomaterials
  • Biomedical Engineering

Cite this